A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

Conditions

• Advanced-stage Solid Tumors

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• JNJ-89862175 — DRUG
  JNJ-89862175 will be administered.

Study Details

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.

Key Dates

Start date

Oct 10, 2025

Status verified

Jun 2026

Primary completion

Dec 15, 2026

Completion

Aug 15, 2028

Study Design

Enrollment

360 participants (estimated)

Allocation

NA

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: JNJ-89862175
  Participants will receive JNJ-89862175 in Part 1 to determine the recommended phase 2 doses (RP2Ds). Dose-escalation and de-escalation will be based on study evaluation team (SET) decision. In Part 2, participants will receive JNJ-89862175 at the RP2Ds determined in Part 1.

Primary Outcome Measure

Part 1: Number of Participants with Dose-Limiting Toxicity (DLTs) [ Time Frame: Up to 21 days ]

Central Contacts

• Study Contact
  844-434-4210
  [email protected]

Locations (2)

Find similar trials in Orlando, FL